Reckitt Benckiser shells $1.4B to settle US probe; NICE backs diabetes, psoriasis treatments
→ British group Reckitt Benckiser (RB) has agreed to pay the US Department of Justice (DoJ) and the Federal Trade Commission $1.4 billion to resolve a sweeping investigation into the sales and marketing practices of the opioid addiction treatment, Suboxone film, sold by its former prescription pharmaceuticals business Indivior, which was spun out in 2014. In April, Indivior was charged by the DoJ for claiming the product was more effective and safer than rival drugs, despite the lack of evidence supporting that claim.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.